Showing results (121-130 of 133) with videos related to
Sort By:
Pageof 14
The Journal of Clinical Investigation|December 15, 2021
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancersMark Yarchoan, Leslie Cope, Amanda N Ruggieri, et al.Cancer Discovery|July 16, 2026
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohortsS Daniel Haldar, Amanda L Huff, Hejia Henry Wang, et al.Biorxiv : the Preprint Server for Biology|October 10, 2024
Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic respondersDimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel, et al.Cell Systems|April 20, 2023
Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spacesAtul Deshpande, Melanie Loth, Dimitrios N Sidiropoulos, et al.Cancer Research Communications|September 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor TherapyHoward L Li, Soren Charmsaz, Mari Nakazawa, et al.Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.Biorxiv : the Preprint Server for Biology|October 31, 2023
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockadeDaniel H Shu, Won Jin Ho, Luciane T Kagohara, et al.Cancer Research|September 5, 2019
Recent Developments and Therapeutic Strategies against Hepatocellular CarcinomaMark Yarchoan, Parul Agarwal, Augusto Villanueva, et al.Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.Cell Reports. Medicine|March 20, 2024
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinomaAllison M Kirk, Jeremy Chase Crawford, Ching-Heng Chou, et al.Pageof 14